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Abstract
Recently, we demonstrated that GM1 micelles transport paclitaxel and doxorubicin with high efficiency. When 
this GM1-drugs complex is incubated with whole serum, albumin was the only one protein that binds spontaneously 
to form GM1-drug-albumin complex. Here, we show that, under specific physicochemical conditions, these micelles 
interact with antibodies forming GM1-IgG complexes. The load of IgG in GM1 reaches a maximum at ratios of 1/4 
(w / w) incubating to 4.5 and preheating the micelles of GM1 at 55-60°C. The IgG of the GM1-IgG complex obtained 
under these experimental conditions retains the biological activity against the soluble and cellular antigens and is not 
displaced from the micelles in the presence of albumin, the main competitive binding protein.
Treatment of GM1-IgG with pepsin, does not show the breakage of the IgG like control of free IgG, suggesting that 
IgG is deeply bound into GM1, probably via Fc. Moreover, the presence of 1 M NaCl does not prevent neither dissociate 
the complex, suggesting the hydrophobic nature of the interaction. The DLS and TEM results shows that GM1-IgG 
complexes have sizes significantly higher than those of GM1 micelles; this is directly related to the amount of IgG 
loaded. On the other hand GM1-IgG complex also retain the ability to encapsulate oncological drugs, but, an adequate 
sequence must be followed during the preparation, in order to obtain efficient GM1-drug-IgG ternary complexes. 
Moreover, the presence of IgG into GM1-oncological drugs complex do not affect the release or the citotoxic activity of 
the encapsulated molecules such as Ptx or Doxo.
Keywords: Immunomicelles; Monosialoganglioside (GM1); Targeted 
drug delivery; Nanomedicine; Cancer
Introduction
The use of monoclonal antibodies targeting to cell surface antigens 
on malignant cells, that are generally more numerous on the surface 
of cancer cells than healthy cells, has positively recognized itself as 
an effective approach for therapy of solid and hematological tumors. 
They are designed to function in different ways as flagging cancer cells, 
triggering cell-membrane destruction, blocking cell growth, preventing 
blood vessel growth, blocking immune system inhibitors, directly 
attacking cancer cells, delivering radiation treatment and delivering 
chemotherapy. Even, one strategy that has received much attention in 
recent times is the chemistry of attaching antibodies to nanocarriers 
for targeted cancer therapy to achieve a high degree of selectivity and 
improve drug absorption or to be used as a dual system. In this sense, 
numerous procedures have been described for attaching antibodies to 
carriers and even to drugs for active targeting, including covalent and 
non-covalent approaches [1-7]. In all cases, the main goal is to bind the 
antibody without losing its functionality after attachment. One of the 
most commonly used binding methods is through chemical conjugation 
using cross-linking reagents. This crosslinking leads to a more stable 
binding, which could improve the physicochemical stability and half-
life of the antibodies and prevent competitive displacement by the blood 
components. Simultaneously, the incorporation of antibodies into 
the vehicles carrying the drugs offers clear advantages over the direct 
conjugation of the antibody into the drug itself [8,9], such as higher 
drug loading capacity and protection of the drug reaction conjugation. 
However, these methods often alter the biological functions of 
antibodies as well as drug transport structures. 
Regarding the non-covalent binding of antibodies to the 
transporters, although methodologically it may be simpler and easier 
to carry out, there are a number of factors to consider since non-
specific binding has less stability, which can determine the desorption 
or displacement from antibody by serum proteins which compete 
for adsorption sites [1,10,11]. Similarly, the correct orientation of 
antibody molecules is a key factor that can reduce or even eliminate 
the effectiveness of target binding. Therefore, depending on the chosen 
procedures, it is important to optimize the conditions and characterize 
the complexes obtained in terms of their physical properties and 
biological activity.
In previous studies, we describe a self-assembled sialo-
glycosphingolipid (GM1) micellar system capable of loading and 
releasing hydrophobic (paclitaxel) and hydrophilic drugs (doxorubicin), 
or both, with high efficiency [12,13]. We also found that GM1 micelles 
loaded with drugs interact spontaneously with albumin (Human 
Serum Albumin-HSA) to give GM1-drug-HSA complexes. Here, we 
demonstrate that subtle specific changes in the conditions that affect 
both components GM1 and IgG it is possible to obtain the complex of 
GM1-IgG. We analyze influence of various physical factors in the non-
covalent interaction, specially the temperature that modify substantially 
the properties of GM1 micelles [14] and the pH [15,16] to optimize 
amount of mAb bound to the micelles, its stability, biological activity 
and the capability to load oncological drugs.
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Materials and Methods
Materials
GM1 was supplied by TRB Pharma S.A. Total human IgG 
antibodies were provided by Laboratory of Hemoderivados, National 
University of Córdoba (Córdoba, Argentina). Rubella IgG antibodies 
were measured using Immulite / Immulite 1000 analyzer and anti-
HBs were analyzed using Roche Elecsys immunoassay analyzer. 
Monoclonal antibodies CD4-FITC / CD8-PE / CD3-PC5 (OptiClone) 
were from Immunotech, Beckman, France. Anti-HER-2/neu (4B5) 
rabbit monoclonal primary antibody and anti-Ki-67 primary rabbit 
monoclonal antibody (IgG) directed against C-terminal portion of 
Ki-67 antigen were from Ventana Medical Systems, Inc., USA. Anti-
FR IgG primary antibodies (folate receptor-targeted antibody), anti-
LDLR IgG (anti-LDL receptor targeted antibody) and anti-CD44 IgG 
(antibody targeted against the receptor for hyaluronic acid) were 
purchased from Sigma Aldrich. Paclitaxel (Ptx) was acquired from 
Yunnan Smandbet Co. Ltd. (Kumming, China). The stock solutions 
of Ptx were prepared by dissolving the drug in dimethylsulfoxide 
(DMSO) at a final concentration of 50 mg mL-1. Doxorubicin (Doxo) 
was obtained from Sigma. Stock solutions of Doxo were prepared in 
physiologic solution at 6 mg mL-1. Sephadex G-25 and G200 columns 
were purchased from GE Healthcare (Buckinghamshire, UK). All 
other reagents were of analytical grade, used as received from Merck 
(Darmstadt, Germany). 
Methods
Cell lines cultures: The following continuous cell lines were used: 
human cervical epithelioma cells (HeLa), non-small cell human lung 
carcinoma cells (H1299) and highly metastatic mouse melanoma cells 
(B16).
For cell cultures, MEM for HeLa and DMEM-F12 for H1299 and B16 
cells, were supplemented with irradiated fetal calf serum (NATOCOR, 
Córdoba, Argentina) at 1 or 10% (v/v) according to maintenance or 
growth conditions, respectively.
Preparation of IgG antibodies coupled to GM1 micelles: Stock 
solution of 250 mg.ml-1 GM1 was prepared in bidistilled water 24 h prior 
to use. The solutions were maintained at 4-8°C for 24 h and centrifuged 
at 50,000 g for 15 min. The supernatant was finally filtered through 0.22 
μm. The micelles (GM1) were then incubated with human IgG under 
different conditions of pHs (3, 4.5 and 7.4), temperatures (4, 25, 37, 45 
and 55°C) and times (from 2 to 24 h). 
The results of these assays were analyzed by chromatographic 
analysis.
Size exclusion chromatography (SEC): The GM1-IgG complexes 
were isolated and quantified by size exclusion chromatography. Samples 
and controls were run on an Åkta Explorer 100 system (GE Healthcare) 
fitted with a Superdex 200 column, previously equilibrated with 50 mM 
phosphate buffer (pH 7.4) and 150 mM NaCl at a rate of 0.4 mL min-1. 
The elution profile was followed using a UV-visible detector at 200 and 
280 nm for GM1 micelles and protein respectively [17]. 
Native SDS-PAGE analysis: The identification of antibodies 
after incorporation into the micelles and eluted by size exclusion 
chromatography was detected by SDS-PAGE and compared with the 
native antibody control. The gels were run under native conditions 
(without 2-mercaptoethanol) using a BioRad Mini-Protean II kit at 
a constant voltage of 200 V in Tris/glycine/SDS buffer. The gels were 
stained with Coomassie blue. 
Determination of IgG concentration: IgG concentration was 
determined using a Lowry assay [18] or by direct absorbance at 280 nm. 
Digestion of IgG incorporated in GM1 micelles with pepsin: 20 µl 
(0, 4 mg) of pepsin under acid conditions was added to 1 ml of GM1-
IgG complex (5/1 w/w) previously prepared. The mixture was incubated 
at 37°C in buffer pH 4.5 in a shaking water bath and 20 µl aliquots were 
taken at 30 min for IgG control and at 15, 30, 60 and 90 min for GM1-
IgG for analysis by gel electrophoresis. 
Particle size and size distribution: Average particle size and size 
distribution of the nanoparticles were measured by laser light scattering 
(LLS, Delsa TM Nano, Beckman Coulter Instruments). The samples 
were diluted with PBS buffer pH 7.4 and filtered before measurement. 
Data were analyzed using Delsa ™ Nano Beckman Coulter software 
(version 2.2). All measurements were done in triplicate, for each of 
three micelle-independent batches. 
Surface charge: The zeta potential of the GM1-IgG complexes was 
determined using a Delsa TM Nano zeta potential analyzer (Beckman 
Coulter Instruments) at room temperature. The samples were prepared 
by diluting the micelle solutions with PBS buffer pH 7.4. Particle sizes 
of the micelles were measured to assure that micellar structure was 
intact. Samples were diluted with PBS buffer (145 mM NaCl) pH 7.4 
and filtered prior to measurement. The zeta potential was determined 
in triplicate and results were calculated automatically by the analyzer.
Transmission electron microscopy (TEM): A JEOL JEM-1200 EX 
II transmission electron microscope was used at 300000 X to establish 
the morphology of the modified micelles. 50 μl of each sample was 
loaded onto a carbon grid, incubated for 5 min and the grid was then 
dried. The gratings were then incubated with 50 μl of a 10% uranyl 
acetate solution for 1 min, dried and taken under a microscope for 
observation. 
Drug encapsulation and loading efficiency: To assess whether IgG 
binding to GM1 micelles affects the loading capacity of the micelle, we 
evaluated the load of increasing amounts of Ptx or Doxo in GM1-IgG 
micelles of 10 mg.mL-1 to reach micelle/drug molar ratios from 50/1 
to1/1. Drug loading was performed at 20°C for 30 min before incubating 
the samples at 4°C for 24 h. After incubation time, the samples were 
dialyzed against PBS buffer pH 7.4 for 24 h at 4°C to remove the free 
drugs. In addition, the influence of the loading order of the drug and 
IgG was analyzed. 
Determination of Ptx concentration: Ptx concentration was 
measured on a Curosil B C18 column (250×3.20 mm I.D., particle size 
5 μm) and a Curosil BC18 guard column (30 × 4.60 mm I.D., particle 
size 5 μm) supplied by Phenomenex as we previously described [11]. 
The mobile phase was 60% (v/v) acetonitrile and 40% (v/v) bidistilled 
water. Flow rate was 0.7 mL min-1 and the eluent was monitored at 227 
nm. Chromatography was performed at ambient temperature (20°C). 
Validation of the method was carried out according to FDA Guidance 
for Bioanalytical Method Validation. 
Determination of doxo concentration: Doxo concentration 
was determined by absorbance at 490 nm using a calibration curve 
performed with a standard solution of Doxo in physiologic solution, as 
described by Abraham et al. [19]. 
Recognition properties of antibodies bound to GM1 micelles: 
The following methods were used to evaluate the functionality of the 
mAb on the micelle surface. 
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Flow cytometry: A combination of three anti-CD4-FITC / CD8-
PE / CD3-PC5 (OptiClone) fluorescent monoclonal antibodies, 
previously absorbed on the micelles and eluted through a size exclusion 
column (Sephadex G- 200) was incubated with a whole blood sample. 
After incubation, the red blood cells were lysed using a non-washed 
procedure, the processed sample was then directly introduced into 
the flow cytometer for analysis. After excitation at 488 nm, each 
fluorescent marker emitted light at different wavelengths, allowing 
the simultaneous study of CD4, CD8 and CD3 antigens, respectively. 
The use of dispersion diagrams (representation of lateral dispersion 
vs. frontal dispersion) allows discrimination of lymphocytes waste, 
monocytes and polymorphonuclear cells.
As controls, free antibodies and uncoated micelles were analyzed.
Chemiluminescent immunoassay: A solid-phase, sequential 
chemiluminescent immunoassay IMMULITE/IMMULITE 1000 
Rubella Quantitative IgG for in vitro diagnostics was performed to 
determine the functionality of the anti-Rub IgG antibodies absorbed 
on GM1 micelles. First, anti-Rub IgG antibodies were absorbed at the 
experimental conditions selected. Samples were then eluted by a size 
exclusion column to remove free antibodies. Finally, their biological 
activity was measured and compared with standard anti-Rub IgG 
antibodies. Likewise, anti-HBs IgG antibodies were absorbed into GM1 
micelles and eluted through a size exclusion column to separate the free 
antibodies. Subsequently, their biological activity with standard anti-
HBs IgG antibodies was measured and compared by a sandwich-type 
chemiluminescent immunoassay against hepatitis B surface antigen 
(HBsAg).
Immunohistochemistry: Anti-HER-2/neu and rabbit anti-Ki-67 
IgG primary monoclonal antibodies were absorbed into GM1 micelles, 
under pre-established experimental conditions and then incubated 
with tumor tissue sections, which express the specific antigen, fixed in 
formalin for 16 to 32 min. Finally, the tissues with the samples were 
stained on a slide, with the detection kit provided by Ventana®.
The ability of antibodies to recognize their specific antigen after 
being absorbed into the micelles was compared to that of the same free 
antibodies using images obtained by optical microscopy of consecutive 
tissue sections.
In vitro interaction assays of GM1-antibody complexes with 
cells expressing specific receptors: Different specific antibodies, 
anti-FR, anti-CD44, anti-HER-2/neu and anti-LDLR, were used to 
evaluate the surface expression of specific receptors in the different 
cell lines mentioned above. In parallel, cells were incubated with the 
same antibodies adsorbed into GM1 micelles to evaluate the specific 
interaction of GM1-anti receptor IgG with the cells. Briefly, confluent 
monolayers were incubated with the different anti-receptor antibodies, 
at concentrations between 1 and 20 μg.ml-1 and 4 to 24 h at 37°C. After 
incubation, cells were washed extensively with PBS to remove unreacted 
material and a Peroxidase enzyme-labeled anti-IgG secondary antibody 
was added at different dilutions for 2 h at 37°C. Finally, the monolayers 
were washed again to remove the unreacted labeled anti-antibodies and 
the bound material was analyzed by colorimetric spectrophotometry. 
The final colorimetric evaluation was performed after the addition of 
a specific substrate (chromogenic), the ortophenylenediamine (OPD), 
on which the peroxidase enzyme acts and gives an observable and 
quantifiable colored reaction product. Absorbance measurements 
were performed on an automated plate reader (BioRad., CA, USA) 
at λ = 490 nm. The reaction blank for the absorbance of each sample 
was discounted. The untreated monolayers to which only the labeled 
secondary antibody and the chromogen were added for the reaction 
were taken as reaction blank. The results represent mean values of three 
measurements and their respective deviations. 
In vitro cytotoxicity of Paclitaxel or doxorubicin loaded in GM1-
drug-antibody complexes: Cytotoxicity assays were performed using the 
cell lines which exhibited the expression of specific receptors (+), such as 
the non-small cell (H1299) human lung carcinoma cells, CD44 receptor 
(+) highly metastatic mouse melanoma cells (B16), FR and LDLR (+) and 
human cervical epithelial cells (HeLa), CD44 receptor (+).
Confluent monolayers grown in 96 well plates were incubated 
with GM1-Doxo or GM1- Doxo- IgG micelles with different Doxo 
final concentrations (10, 25, 50 μg.ml-1) at different times (30 min to 
8 h). After each time, the medium with the sample was replaced by 
fresh medium and incubated 24 h at 37°C and 5% CO2. After 24 h the 
cells were washed three times with PBS, fixed with 10% formaldehyde 
and then stained with a solution of 0.4% crystal violet in methanol, 
widely used to evaluate the cytotoxic activity of drugs or biomaterials. 
Subsequently a solution of 5% acetic acid was added to the stained cells 
to dissolve the color after 10-15 min absorbance was determined. 
Quantitative analysis (colorimetric assay of the fixed cells) was 
performed by absorbance measurements on an automated plate reader 
(Bio-Rad., CA, USA) at 620 nm. Cell viability was calculated and 
compared between samples. Untreated cells incubated with culture 
medium only were taken as negative control, 100% cell survival. 
The results represent mean values of three measurements and their 
respective deviations. 
The assays with Ptx were performed in a similar way to those of 
Doxo; cells monolayers were incubated with Ptx, GM1-Ptx or GM1-
Ptx- anti receptor IgG for 24 h and results were quantitatively analyzed 
by crystal violet assay.
Results
Characterization of the interaction of IgG antibodies with 
GM1 micelles
Previously, we described that GM1 micelles interact spontaneously 
with albumin, but not with immunoglobulins. In this work, we 
evaluated if modifying properties of GM1 or IgG under different 
experimental conditions allow achieving the interaction between 
micelles and antibodies. To do this, we begin evaluating whether the 
modification of the structure of IgG by changes in pH, in a range of 
4.5 to 7.5, leads to interaction. The interaction was evaluated by size 
exclusion chromatography. Considering that pure GM1 micelles 
(~375 kDa) eluted with the V0 (unretained fraction) of the column 
(data not shown) and IgG fraction (150 kDa) eluted in the fraction 
corresponding to a volume about 6 ml. When GM1 micelles (20 mg.ml-1 
) were incubated with IgG (5 mg.ml-1 ) at 25°C at pH7 and eluted at 
pH 7.4 each component kept its original profile with only less that 5 % 
of the added immunoglobulin interacts with micelles confirming that 
no association occurs under this pH condition (Figure 1A). However, 
when GM1 micelles (20 mg.ml-1) were incubated with IgG (5 mg.ml-1) 
and eluted at pH 4.5, a condition that produces changes in the Fc by 
exposure of hydrophobic components but it does not affect IgG activity 
nor GM1 structure, the elution profile showed a shift to a unique high 
molecular weight specie (≥ 375 kDa) where practically all the IgG elutes 
with the GM1 micelles, demonstrating a physical association between 
these two fractions. On the other hand, when the incubation is carried 
out at pH 4.5 and then eluted at pH 7, the appearance of a second peak 
of 150 kDa, corresponding to the IgG, indicate a partial dissociation of 
the complex.
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Considering the reversible conformational denaturation of the IgG 
at acidic pH, with the consequent exposure of hydrophobic residues, 
mainly in the Fc region [15,16], our results about the binding of IgG to 
GM1 micelles at pH 4.5 suggest an interaction of hydrophobic nature. 
To better understand the nature of the GM1-IgG interaction at pH 4.5, 
we added 1 M NaCl to dissociate a possible electrostatic interaction 
of the complex, which did not happen, reinforcing the concept of the 
hydrophobic nature of the interaction. 
To evaluate the effect of temperature on GM1-IgG interaction, we 
incubate the complex in two different experimental conditions and 
then molecular exclusion chromatography was also used. First one, 
increasing the incubation temperature in a range from 4°C until to 
45°C, the maximum temperature that not affect the biological activity 
of IgG. Figure 1B show that the binding of the immunoglobulins to the 
GM1 micelles increase around from 4-5 times from 4°C to 45°C. 
The second one is an assay where the temperature affects only the 
GM1 micelles. It has been reported that temperatures above 55°C induce 
the release of water molecules bound to the oligosaccharide chain of 
gangliosides, resulting in a significant reduction of the hydrophilic 
portion, accompanied by a slight extension of the hydrophobic region 
of the micelles [20,21]. When GM1 micelles were preheated at 55°C 
for 30 min at pH 4.5 and then stabilized at room temperature, the 
binding of IgG to this GM1 was higher than that for GM1-IgG complex 
heated together at 45°C described above (Figure 1C). These results, 
demonstrate that temperature and especially those that affect the GM1 
play a key role in the interaction. 
A common disadvantage of the physical adsorption of antibodies 
to nanocarriers is the competitive displacement by blood components 
[1,10,11]. Considering the spontaneous association of albumin (HSA) 
with GM1, demonstrated in previous reports of our own and other 
authors [12,17,22,23], we analyzed whether the presence of albumin 
affects the interaction of immunoglobulins with GM1 micelles.
To evaluate this, GM1 micelles (20 mg.ml-1) at pH 4.5 were 
incubated during 30 min at 45°C with a solution containing both IgG 
(5 mg.ml-1) with increasing concentrations HSA from 0 to 8.8 mg/ml 
and then the elution profile of proteins was analyzed. Figure 2A shows 
that the presence of increasing amounts of HSA (from 0 to 8.8 mg.ml-1) 
induced the appearance of a new peak which correlates with the elution 
pattern of IgG (150 kDa) that increases with albumin concentration. 
These results demonstrate that, under this experimental condition, 
there is a competitive binding site for both proteins in GM1 micelles. 
Figure 2B shows the SDS-PAGE analysis of fractions eluted from the 
size exclusion column. With 2.2 mg.ml-1 HSA (Figure 2B- SDS-PAGE 
a), both proteins HSA and IgG appear to be bound to GM1 micelles 
and elute together in the column as can be seen in the same fractions 
of SDS-PAGE, whereas in presence of HSA 4.4 and 8.8 mg.ml-1 (2B- 
SDS-PAGE b) and (2B- SDS-PAGE c), only HSA can be seen in the 
initial fractions of SDS-PAGE while IgG appear in retarded fraction 
corresponding with MW 150 kDa, confirming the results described 
above.
Interestingly, when the complex of GM1-IgG is obtained at pH 
4.5 and then adjusted to pH 7.4, the addition of HSA at 4, 4 and 8, 8 
Figure 1: A- Pattern of chromatographic elution on Superdex 200® of IgG binding to GM1 at different pH:  IgG control at pH 7.4 ( ), GM1 and IgG incubated and 
eluted pH 4.5 (○); GM1 and IgG incubated pH 4.5 and eluted pH 7.4 (▲) and GM1 and IgG incubated and eluted at pH 7.4 (γ). B- Pattern of chromatographic elution 
on Superdex 200® of IgG binding to GM1 at different temperatures.  Samples of GM1 and IgG at pH 4.5 were incubated at temperatures indicated below for 30 min 
and then the elution was done at 25°C.  IgG control ( ), GM1 and IgG at: 4°C (▲); 25°C (+); 37°C (γ) and 45°C (⊄).  C- Pattern of chromatographic elution on 
Superdex 200®  of  IgG binding to pre-heated GM1at 55°C and then allowed to reach 25°C and incubated with IgG (γ)  ; IgG and GM1 incubated at 45°C and eluted 
25°C (⊄) and IgG control  ( ). All samples were run at pH 4.5. 
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mg.ml-1 was not able to displaced the IgG such as describe above when 
both proteins were co incubated at same time since the complex GM1-
IgG eluted in V0, suggesting that under physiological conditions IgG 
would remain attached to the micelles.
As mentioned above, the binding of IgG to micelles is optimal 
after preincubating GM1 micelles at 55°C and allowed to reach 
room temperature before incubating with IgG at pH 4.5. Using this 
experimental condition, we evaluated the maximum binding capacity 
of IgG to a fixed concentration of GM1 micelles. The result revealed 
that GM1 reaches its maximum capability to bind IgG at GM1/IgG 
ratio 4/1 w/w (data not shown). Considering the apparent MW of the 
GM1 micelles which, when heated to 55°C, is 320 kDa [20,21] and 
the MW of the IgG, of 150 kDa, the complex would be formed by two 
antibody units per micelle of GM1. 
Physicochemical characterization of GM1-IgG micelles
Here we characterize the physicochemical properties of these 
mixed micelles. Studies about particle diameter, polydispersity index, 
surface morphology and z potential were assessed. Table 1 shows the 
results of these studies of GM1-IgG in comparison with free GM1 
micelles. The GM1-IgG micelles had a mean diameter in the range of 
25.0 nm, while GM1 micelles shows only 11.9 nm, which shows that 
the presence of IgG on micellar surface increased the size about 100%. 
The polydispersity of different composition of GM1-IgG micelles (10/1 
and 4/1 GM1/IgG weight /weight ratio) were very similar but with 
relatively high values of about 0.28 ± 0.09, however this result does not 
appear to be related to the amount of IgG on the surface. On the other 
hands, using transmission electron microscopy we also can visualize 
this size changes. The images of Figure 3A shows the particle size of 
GM1 micelles and in Figure 3B the changes observed in the GM1/IgG 
4/1 weight /weight ratio that also show a longer dispersion interval. 
Next we evaluate whether the presence of IgG in the surface of 
GM1 micelles induce changes on surface charge of final structure. 
Table 1 shows that the zeta potential values  obtained for GM1-IgG 
in proportions of 10/1 and 4/1 w/w, were -10.6 ± 0.3 and -11.8 ± 1.2 
respectively and -8.1 ± 1.0 for the micelles of GM1 alone. These results 
seems to indicate no substantial changes in zeta potential after the 
insertion of a high molecular weight protein like IgG into micelles, 
however, taking into account that GM1-IgG micelles were prepared 
from GM1 micelles preheated to 55 °C, that show a zeta potential of 
-23.6 ± 1.9, the zeta potential values of the complex would indicate a 
substantial molecular reorganization according to these results.
Topology of the IgG in the micellar structure
After demonstration of GM1-IgG interaction and the 
characterization of the physicochemical properties, we inquired about 
the final orientation of immunoglobulin in the micelle structure. To do 
this, we performed a proteolityc assay with pepsin, an enzyme which 
specifically cuts IgG separating Fab region from fragments of low 
molecular weight of Fc. 
The results shows that pepsin on free IgG it produces the release of 
Fab fragment, however, under similar condition very little or none IgG 
was cleaved by pepsin from GM1-IgG complex, which suggest that the 
immunoglobulin would be bound to the micelle by the Fc region of the 
molecule, keeping the specific recognition of IgG (Figure 4). 
Biological activity of antibodies associated with micelle surface
Here we evaluate whether the IgG incorporated in the GM1 
micelles retain the biological activity by measurement the capability to 
Figure 2: Patterns of size-exclusion chromatographic GM1-IgG complex (20 
mg.ml-1 GM1 and 5 mg.ml-1 IgG) incubated with increasing concentration of 
HSA at pH 4.5.  A- Chromatography on Superdex 200® of GM1-IgG, GM1-IgG 
with 2.2 mg.ml-1 of HSA (□), GM1-IgG with 4.4 mg.ml-1 of HSA (▲) and GM1-
IgG with 8.8 mg.ml-1 (○) of HSA. B- Native SDS-PAGE of elution fractions of 
size-exclusion chromatographic of GM1-IgG complex incubated with different 
amounts of HSA at pH 4.5. Lanes 1-2: IgG and HSA standards; Lanes 3–10: 
profile elution of: a: GM1-IgG micelles with 2.2 mg.ml-1 HSA; b: GM1-IgG 
micelles with 4.4 mg.ml-1 HSA and c: GM1-IgG micelles with 8.8 mg.ml-1 HSA. 
Parameters
Samples
IgG GM1
GM1 1-Oct 1-Apr
(heated 55°C) GM1/IgG GM1/IgG
 w/w ratio w/w ratio
MD (nm) 6.4 ± 2 14.2 ± 3 11.9 ± 2 20.8 ± 2 25.1 ± 2
PI 0.16 ± 0.06 0.17 ± 0.08 0.11 ± 0.03 0.28 ± 0.09 0.28 ± 0.08
z (mV) -7.8 ± 1.1 -8.1 ± 1.0 -23.6 ± 1.9 -10.6 ± 0.3 -11.8 ± 1.2
Table 1: Physicochemical characteristics of GM1 micelles and GM1-IgG modified 
micelles. 
A B 
Figure 3: Electron micrography of GM1 heated at 55°C (A) and GM1-IgG 
mixed micelles (B). X300000. Size bar: 100 nm. 
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recognize three different antigen species such as 1- soluble antigens, 
2-cell surface antigens and 3- antigen expressed in sections of human 
tumor tissues.
For the first example, to analyze the recognition of soluble antigen, 
we used an anti-Rub IgG from a commercial kit of rubella virus 
adsorbed to the GM1 micelle. The biological activity of the antibody 
was determined by a chemiluminescence enzyme immunoassay. Table 
2 shows that the purified complex of GM1-anti-Rubella virus antibodies 
retains their specific recognition ability against soluble antigens with a 
similar activity than control of anti-Rubella virus antibodies. Moreover, 
it was also observed a direct quantitative relationship between the 
biological activity and the amount of antibody adsorbed on the micelle. 
Nonspecific IgG antibodies bound to GM1 micelles were used as 
controls to rule out non-specific binding.
To evaluate the activity of GM1-antibodies against antigens located 
in the cellular surface we used a combination of three fluorescent 
monoclonal antibodies, anti-CD4-FITC /CD8-PE /CD3-PC5 
(OptiClone), which were loaded onto GM1 and purified as GM1-IgG 
as mentioned before. The mixture was incubated with whole blood 
samples, after which red blood cells were lysed using a no-wash assay 
and finally the samples were analyzed by flow cytometry. The results 
indicate that the loaded of the immunoglobulins to the micelles does 
not affect their specific recognition property against antigens expressed 
in cells in suspension (Table 3). 
On the hand the interaction of the GM1-antibodies with another 
class of cell surface antigen such as receptor were also evaluated. The 
specific receptors expressed on the cell surface was evaluated using anti-
FR IgG, anti-CD44 IgG and anti-LDLR antibodies, which were absorbed 
to GM1 micelles and analyzed by colorimetric spectrophotometry. The 
results reveal no significant differences between the antibodies loaded 
to the micelles compared to the controls (Table 4). GM1 micelles alone 
and loaded with total human IgG were used as controls to confirm 
absence of nonspecific binding. All these results seem to prove that the 
incorporation of the antibodies into the micellar structure does not 
affect their functionality. 
Finally we also studied the activity of anti-Her2 or anti-KI67 
antibodies loaded in GM1 micelles by immune-histochemistry (IHC) to 
evaluate recognition of specific antigen expressed in sections of human 
tumor tissues. Immuno histochemical visualization of the antigen-
antibody complex was performed by staining with a fluorochrome or 
enzyme, depending on the labeling of the antibody. Figure 5 shows that 
the GM1-antibodies are able to recognize their specific antigens on 
tissues, in this case the epidermal growth factor and the nuclear protein 
KI-67 in similar extension that control of free antibodies.
Effect of IgG in GM1 micelles on drugs encapsulation, release 
and cytotoxic activity of drugs
In previous reports we demonstrate that GM1 micelles were able to 
load hydrophobic or hydrophilic drugs such Ptx, Dtx, Doxo and AmB 
[12-13,17]. Here we evaluate capability of this GM1-IgG complex to 
discern whether this modification affects their drug loading capacity, 
drug release or the pharmacological activity.
We found that increasing the amount of IgG in the GM1-IgG 
complex produce a decreased in the amount of hydrophobic drug Ptx 
loaded in GM1-IgG micelles, Table 5 However, when the incorporation 
of the Ptx on GM1 occurs before the binding to IgG, the efficiency of 
Ptx encapsulation remain similar to that described above for pure GM1 
micelles [12]. These results suggest that IgG could be located in external 
domains of GM1 micelles, which prevents subsequent entry of Ptx in 
the hydrophobic region of the micelles. By other hands, suggest that 
Ptx could be located deeply in the GM1 micelles as was proposed in 
previous report [12] a condition that not affect the binding of de IgG to 
GM1 micelles to form finally the GM1-Ptx-IgG complex. 
The loaded of water soluble drug Doxorubicine into GM1-IgG 
micelles is substantially affected by the presence of IgG. At the GM1/
IgG (4/1 w/w ratio) the saturating condition, the amount of Doxo 
that can be incorporated decreases four times with respect to its 
optimum capability to be loaded in free GM1 micelles (at molar ratio 
5/1 GM1/Doxo). In this case, unlike what happens with Ptx, the load 
of increasing concentrations of Doxo into free GM1 micelles before 
adding IgG, produce a significantly decrease in the amount of IgG 
that binds to GM1-Doxo micelle. When GM1-Doxo complex is 
obtained at molar ratio of 5/1 GM1-Doxo, the maximun capability 
 
         1        2        3              4        5       6       7 
Figure 4: Treatment of free IgG and IgG loaded on GM1 micelles with 
pepsin. Samples of free IgG and GM1-IgG at pH 4,5 were incubated at room 
temperature for different times with pepsin and then subjected to SDS-PAGE 
in non denaturating conditions. Lane 1: IgG control; Lane 2: IgG treated 30 min 
with pepsin; Lane 3: Pepsin control; lines 4-7: GM1-IgG treated with pepsin at 
different times: 15, 30, 60, 90 min.   
Sample Biological Activity mUI/ml
10 µl anti-Rub antibody in PBS buffer 11.3 +/- 4.0
4 mg GM1 micelles + 10 µl anti-Rub antibody in PBS buffer 11.1 +/- 4.2
4 mg GM1 micelles + 30 µl anti-Rub antibody in PBS buffer 33.3 +/- 6.1
Table 2: Test IMMULITE 1000. Quantitative measurement of IgG antibodies to 
rubella virus. Solid-phase, sequential chemiluminescent immunoassay for in vitro 
diagnostic use. 
Monoclonal antibody CD4+ CD4+ CD8+ CD8+ CD3+ CD3+
Sample Counts/mm3 %
Counts/
mm3 %
Counts/
mm3 %
Control (+): 5 ul of Three-color 
Antibodies standards in Vf: 50 
ul PBS buffer
2326 56 1039 25 3698 89
GM1 micelles (1 mg) + 5ul 
of Three-color Antibodies 
standards in Vf: 50 ul PBS 
buffer
2410 58 977 23.5 3694 89
Control (-): GM1 micelles (1 
mg) + 5 ul (Anti-Rabbit-FITC) 
Antibody in Vf: 50 ul PBS 
buffer
2 0 3 0 1 0
Table 3: Flow cytometry analysis of GM1 micelles pre-incubated with a three-color 
monoclonal antibody combination (OptiClone). 
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of GM1 to load Doxo [13], the percentage of IgG binding falls almost 
completely (data not shown). These results suggest a competitive 
relationship between Doxo and IgG by common sites within the 
micellar structure. 
 Studies of in vitro release and cytotoxicity activity of paclitaxel 
and doxorubicine loaded in GM1-IgG-drug complexes
Finally, we evaluate the cytotoxic effect of Ptx or Doxo present in 
this GM1-drug-IgG complexes and compare with previously report of 
GM1-Ptx [13], to determine if the presence of the immunoglobulin in 
the micelles produces any change in the biological activity in vitro of 
the loaded drug. 
Paclitaxel was incorporated in two samples of GM1 at GM1-Ptx 
molar ratio 10:1, the maximun binding capability. Then, one sample 
was incubated with IgG (anti-CD44 IgG) in a ratio 4:1 to saturate GM1-
Ptx to obtain GM1-Ptx-IgG complexes, and the citotxic effect of Ptx 
was evaluated on the H1299 cell line using GM1- Ptx -IgG inespecific, and 
GM1-Ptx as controls. The results showed that the cytotoxic activity of 
Ptx were similar in all cases (data not shown). Control of vehicle, GM1-
IgG (anti-CD44), did not show toxic effects on the cellular monolayers 
(data not shown). Similar results were obtained when assays were 
performed with other specific antibodies in their respective susceptible 
cell lines (see materials and methods). 
In the same way, assays performed with Doxo loaded on the 
different GM1-Doxo- IgGspecific formulations did not reveal 
significant differences in cell viability with respect to GM1- Doxo- 
IgGinespecific and GM1-Doxo. These results suggest that the presence of 
the antibody in the micellar structure does not modify the release and 
uptake of the drugs. 
Discussion
The use of antibodies against selectively expressed antigens on 
the surface of cancer cells is a therapeutic strategy widely studied not 
only as directed immunotherapy but also for its potential to selectively 
target drugs or drug delivery systems [24,25]. 
In a previous report [12,13] we demonstrate that GM1 is able to 
load and release hydrophobic and hydrophilic oncological drugs in 
GM1-Drug complex. When this complex is incubated in presence of 
whole serum, there is only one protein, albumin, that spontaneously 
Cell Line Hep-2 B16 H1299
IgG (µg.ml-1) 5 10 15 20 5 10 15 20 5 10 15 20
Sample             
Anti-FR IgG 0.1 0.08 0.13 0.12 0.34 0.53 0.51 0.54 0.3 0.09 0.14 0.11
GM1/Anti-FR IgG 0.06 0.09 0.1 0.11 0.31 0.55 0.56 0.52 0.11 0.07 0.12 0.09
Anti-LDLR IgG 0.36 0.59 0.67 0.71 0.19 0.26 0.36 0.37 0.08 0.12 0.11 0.16
GM1/Anti-LDLR IgG 0.33 0.6 0.7 0.74 0.16 0.25 0.39 0.41 0.08 0.09 0.1 0.12
Anti-CD44 IgG 0.09 0.11 0.13 0.1 0.13 0.17 0.14 0.17 0.33 0.46 0.49 0.51
GM1/Anti-CD44 IgG 0.05 0.08 0.11 0.11 0.09 0.15 0.15 0.18 0.3 0.44 0.51 0.54
Total human IgG 
 0.13  0.11  0.09  0.13  0.09  0.11
antibodies
GM1/Total human IgG
 0.09  0.09  0.1  0.11  0.06  0.09
antibodies
Table 4: Semi-quantitative colorimetric determination by absorbance at 490 nm of antibodies attached to the micelles against surface receptors expressed on in vitro 
cell lines HeLa, H1299, Hep-2 and B16. Anti-FR IgG: anti-folate receptor antibody; anti-CD44 IgG: anti-hyaluronic acid receptor antibody and anti-LDLR IgG: low density 
lipoprotein receptor antibody. 
 Ptx Soluble (%)
Weight ratios
GM1-IgG-Ptx GM1-Ptx-IgG
GM1/IgG (w/w)
15/1 48 98
1-Oct 42 98
1-Aug 16 96
1-Apr 6 99
1-Feb 3 97
Table 5: Loading of Ptx into GM1-IgG micelles at different GM1-IgG weight ratios or into free GM1 micelles and then incubated with IgG at different GM1/IgG weight ratios. 
The loading of Ptx into GM1 and GM1-IgG were done at 20°C for 30 min, and the loading of IgG into GM1 or GM1-Ptx were done at 20°C for 1 h at pH 4.5.
A B 
C D 
Figure 5: Immunohistochemistry images of human tumor tissue sections 
incubated with anti-Her2/neu monoclonal primary Antibody (A), GM1 micelles 
coated with anti-Her2/neu monoclonal primary Antibody (B), anti-Ki-67 
monoclonal primary Antibody (C) and GM1 micelles coated with anti-Ki-67 
monoclonal primary Antibody (D).
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bind in a non-covalent form to GM1-Drug-Albumin complex. In this 
report we describe a new procedure to load IgG into GM1 micelles to 
form GM1-IgG complex that under specific conditions also retain the 
capability of load drugs to generate the GM1-Drug-IgG. 
This complex could be considered a delivery system for an 
immune-chemotherapeutic capable of combining the properties of 
drugs transported in the micelles [26,27] with the specific recognition 
capacity of the antibodies. 
We demonstrate that the load of IgG into GM1 micelles was 
controlled by two principal factors such as the pH and temperature, 
conditions that affect IgG and GM1 structures to allow a non-covalent 
interaction,.
Changes in the pH from pH 7,4 to pH 4.5 produce significative 
increase in the interaction between GM1 micelles with IgG. This 
favorable interaction at pH 4.5 seems not related to changes in GM1 
micelles since no modification were reported by GM1 but related 
to the conformational state that suffer IgG known as "reversible 
conformational denaturation", and especially for Fc fragment [15,16]. 
In this condition, there is a partial exposure of their hydrophobic 
residues of Fc involved in the interaction with micelles. On the other 
hand, the fact that addition of high salt concentrations in the incubation 
media, does not prevent interaction between micelles and antibodies 
reinforce the idea of the hydrophobic nature of the interaction. 
Instead, the temperature was a critical factor for both molecules. 
When IgG and GM1 micelles were co-incubated from 4 to 450C, and 
moreover when free GM1 micelles were pre-heated at 55-600C, there is 
a clear increase in the capability of GM1 to load IgG. 
The temperature shows two phases, until 450C both IgG and GM1 
micelles seems to be modified to improve the interaction, but this 
temperature was the limit of IgG before an irreversible denaturation. 
However the thermal treatment at 55-60°C of free GM1 micelles 
before to incubation with antibodies produces the maximun GM1-
IgG complex. In this case the effect is only for the conformational 
changes in the surface of GM1 micelles due to the dehydration of the 
polar groups of the ganglioside molecule that produce an increase 
of the hydrophobicity that undergoes the micellar structure at that 
temperature [20,21]. Under this experimental condition permit to 
avoids exposure of immunoglobulins to high temperatures, which 
compromise their functionality. After select the optimal interaction 
condition to obtain the more stable GM1-IgG complexes, pH 4,5 and 
heating GM1 micelles 55-60°C, the maximun ratio GM1-IgG was 
reached to 4/1 (w/w). Moreover under this condition the spontaneously 
binding of albumin to GM1 micelles mentioned above, does not occurs. 
The characterization of the size and morphology of this GM1-IgG 
complexes by DLS and TEM showed a size considerably higher than 
that of free GM1 micelles, 25.1 nm and 11.9 nm respectively but with 
a similar rounded morphology, suggesting that IgG do not affect the 
geometry of complex. It is interesting to remark the results obtained 
with pepsin, a well-known protease that cleaves immunoglobulins in 
Fc and Fab fragments, the enzyme causes the release of Fab fragment in 
contact with free IgG, however, when exposed under similar conditions 
to the IgG bound to GM1-IgG complex, pepsin shows little activity on 
the immunoglobulin (Figure 4). Although it cannot be ruled out that 
this behavior respond to steric impediments that prevent the enzyme 
from accessing its target site, this fact may also be a consequence of 
the spatial location of the immunoglobulin in the micelle, with its Fc 
region protected inside. 
On the other hand, we also evaluate whether antibodies retain 
their antigenic recognition ability after its physical association to GM1 
micelles. The assays demonstrate that different specific monoclonal 
antibodies loaded onto GM1 micelles were able to recognize fragments 
of soluble antigens, or located in the cell surface such receptors or 
intracellular antigen used for histochemical. This study suggest that 
this GM1-IgG complex do not show any sterical impediment of IgG 
to react with different antigen. Both results are in agreement with 
the possibility that under this specific condition the insertion of IgG 
into GM1 micelles occurs through Fc leaving the biological active Fab 
fragment. 
The results clearly demonstrate that GM1-IgG complexes are 
able to overcome two of the main drawbacks of using a non-covalent 
binding method, one referring to the displacement of antibodies by 
plasma proteins and the other to the loss of functionality due to a bad 
orientation of antibodies during binding to the micelle. 
It is well known that antibodies are therapeutically useful 
molecules by themselves, capable of producing direct pharmacological 
effects, such as blocking the interaction of a receptor with a ligand, 
interfering with a multimerization process or activating receptor 
internalization or apoptosis of target cells with numerous intermediate 
cell modulation options [9,28]. The incorporation of antibodies into 
micellar structure could be considered as a strategy for improvement in 
the pharmacokinetic and biodistribution properties of the antibodies, 
which often do not achieve the effectiveness sought by low plasma half-
life or because they do not reach the tumor tissues; variables in which 
GM1 micelles could offer substantial advantages such as crossing the 
blood-brain barrier and entering the brain [29]. This encapsulation 
of IgG into micelles of GM1 also could be used for improving the 
biodistribution by facilitating selective tumor accumulation through 
enhanced permeability and retention (EPR) effect [28-30].
On the other hand previously reports by owner and others shows 
that GM1 micelles were able to load and release oncological drugs 
such as Paclitaxel and Doxorubicine and moreover that the complex 
were able to cross brain blood barrier [12,13,29]. In these experimental 
conditions we also shown that GM1-IgG complex retain the capability 
of load drugs such as Ptx or Doxo, although it is necessary to follow a 
specific sequence in order to obtain stable GM1-IgG -drug complexes. 
For Paclitaxel, it must be incorporated into micelles before incubation 
with the antibodies, because the presence of IgG in the micellar 
structure prevents its incorporation. Following the order mentioned, 
Ptx can be loaded up to a GM1/Ptx molar ratio of 5/1 that represent 
is the maximum Ptx loaded capability in GM1 micelles alone, then 
IgG also can be loaded also at maximun weight/weight ratio capability 
GM1-IgG 4:1. These results suggest that antibodies occupy more 
external domains in the micelles structure which are critical for Ptx 
insertion. 
With Doxo, its incorporation depends on the amount of IgG 
bound to the micelle and vice versa. At GM1-IgG 4/1 ratios (w/w) 
complex the amount of Doxo loaded is lower than 25% as was observed 
for GM1 alones, and when the amount of Doxo previously loaded onto 
GM1 micelles increase, the encapsulation IgG decrease until to be not 
detectable. This result suggesting that both molecules, IgG and Doxo, 
share common binding domains in the micelles.
The results of in vitro cytotoxicity assays revealed that drugs into 
GM1-Specific IgG micelles show a similar biological effect to drugs loaded 
into GM1-Non-specific IgG-drug and into GM1 micelles alone. This result 
demonstrates first, that the presence of the immunoglobulin in the 
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micellar structure does not affect the release of the drugs contained 
therein. On the other hand, was unexpected the similar toxicity 
observed for GM1-Drug loaded with specific or unspecific IgG. 
Although some kind of difference could be expected, mainly in the 
kinetics of the activity so, there are many basic points between the in 
vitro and the in vivo system that can be considered in the analysis. First, 
the use of antibodies bound either a nanocarrier or one drug itself is 
based on the potential selectivity of the immunoglobulin against the 
different cell types in the organism, which is a very different for the 
in vitro condition, where the assays are performed with pure cellular 
monolayers of a single cell type in each case. Likewise, there is a great 
variety of dynamic and structural factors that are not reflected in the 
in vitro model. All this, added to the high efficiency of the micellar 
system itself for the in vitro transport and drug delivery. The rapid 
fusion or interaction of GM1 micelles with cells may be masking 
antibody participation, together with the low internalization capacity 
of immunoglobulins. 
Most monoclonal antibodies were developed to fulfill effector 
immune functions and not to internalize. In an active targeting system, 
the antibodies are mainly used as "hooks" to facilitate the binding of the 
nanotransporter to the cell expressing the ligands, increasing retention 
at the site of interest. 
This report opens the possibility to incorporation of antibodies with 
different targets of action in a same nanocarrier that contain oncological 
drugs as a new alternative for different therapeutic purposes. 
Conclusions
The results demonstrate the ability of GM1 micelles to interact and 
incorporate IgG into their structure, maintaining their ability to charge 
drugs with different physicochemical characteristics. In summary, the 
results described show that:
• IgG antibodies can be incorporated into GM1 micelles in a 
stable, simple and efficient manner.
• Incorporated antibody maintains its biological activity of 
recognition of its specific antigen.
• GM1 micelles modified with IgG maintain their capacity to 
carry drugs like Ptx and Doxo, but their preparation requires 
following an appropriate order to obtain the maximum load 
capacity.
• The GM1-IgG -drug model can be proposed as a dual or 
multifunctional system, in which the action of several 
antibodies is combined with the transport of drugs with the 
potential to be used for different therapeutic purposes.
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